<table>
<thead>
  <tr>
    <th align="left" width="250">Trial Name<br>(Study, Year)</th>
    <th align="left" width="200">Eligible Patient Population</th>
    <th align="left" width="280">Treatment Arms</th>
    <th align="left" width="150">Trial Duration</th>
    <th align="left" width="220">Adherence</th>
    <th align="left" width="200">Primary Endpoint</th>
  </tr>
</thead>
   
<tbody>
  <tr>
    <td>Exenatide</td>
  </tr>
  <tr>
    <td>AMIGO-1<br>(DeFronzo et al, 2005)</td>
    <td>Adult patients with inadequately controlled T2DM (HbA1c 7.1-11.0%) on metformin monotherapy (≥ 1500 mg qd) for ≥ 3 months</td>
    <td>A: Exenatide 10 ug bid <br>(N=113)<br><br>
        B: Exenatide 5 ug bid <br>(N=110)<br><br>
        C: Placebo <br>(N=113)
    </td>
    <td>30 weeks</td>
    <td>Treatment completion through week 30 with ≥ 80% of injections:<br><br>
         A: 91%<br>
         B: 90%<br>
         C: 89%<br>
    </td>
    <td>Change in HbA1c from baseline to week 30</td>
  </tr>

 <tr>
    <td>AMIGO-2<br>(Buse et al, 2004)</td>
    <td>Adult patients with inadequately controlled T2DM (HbA1c 7.1-11.0%) on sulfonylurea monotherapy (maximally effective dose equivalent to glimepiride 4 mg qd) for ≥ 3 months</td>
    <td>A: Exenatide 10 ug bid <br>(N=129)<br><br>
        B: Exenatide 5 ug bid <br>(N=125)<br><br>
        C: Placebo <br>(N=123)
    </td>
    <td>30 weeks</td>
    <td>Treatment completion through week 30 with ≥ 80% of injections:<br><br>
         A: 69%<br>
         B: 74%<br>
         C: 59%<br>
    </td>
    <td>Change in HbA1c from baseline to week 30</td>
  </tr>

  
</tbody>
 
</table>
